Cantargia AB
SEK3.14
4
+SEK0.04+1.29% Thursday 15:29
Statistik
Harga Tertinggi Hari
3.2
Harga Terendah Hari
3.04
52M Tertinggi
5.2
52M Terendah
2.56
Volum
84,777
Volum Purata
297,337
Kapasiti Pasaran
569.43M
Nisbah P/E
-
Pendapatan Dividen
-
Dividen
-
Akan Datang
Pendapatan
15NovDijangka
EPS yang dijangka
N/A
EPS sebenar
N/A
Orang Lain Juga Mengikuti
Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti CANTA.ST. Ini bukan cadangan pelaburan.
Peserta
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
BeiGene
BGNE
Kapasiti Pasaran21.34B
Regeneron Pharmaceuticals
REGN
Kapasiti Pasaran130.59B
Incyte
INCY
Kapasiti Pasaran12.65B
Merck
MRK
Kapasiti Pasaran300.25B
Bristol-Myers Squibb
BMY
Kapasiti Pasaran101.27B
AMGEN
AMGN
Kapasiti Pasaran179.38B
Gilead Sciences
GILD
Kapasiti Pasaran98.35B
Mengenai
Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Show more...
CEO
Mr. Goran Forsberg
Pekerja
23
Negara
Sweden